Neovascular age-related macular degeneration (nAMD)
Conditions
Interventions
The wet age-related macular degeneration group:None
Control group:None
Sponsors
The Zhongshan Ophthalmic Center,Sun Yat-sen University
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1. wAMD group: (1) Diagnosed clearly: Confirmed as active wet age-related macular degeneration (wAMD) through fundus examination, OCT, OCTA and/or fluorescein fundus angiography (FFA), with the presence of choroidal neovascularization (CNV). (2) Initial treatment: At the time of diagnosis, it was the first treated eye, meaning no previous treatment for wAMD (including anti-VEGF, PDT, laser, etc.) had been received. (3) Age: 18 - 80 years old. (4) Treatment plan: Had received standard anti-VEGF treatment (such as ranibizumab, conbercept, aflibercept, etc.) and completed at least 3 "loading dose" injections. (5) Data completeness (core): Baseline (within 1 week before treatment): Has complete and high-quality BCVA (best corrected vision), IOP (intraocular pressure), OCT and OCTA examination records. Follow-up (e.g., 1 month after the loading dose): Has complete and high-quality BCVA, IOP, OCT and OCTA examination records. Image quality: All OCT and OCTA images used for analysis have good quality, without obvious motion artifacts, occlusion or slices, and can clearly distinguish the structures of the retina and the morphology of CNV. 2. Control group: (1) Age-matched: Age 18 - 80 years old, and matched with the age distribution of the study group. (2) Eye health: Normal fundus examination, or only a few small hard nuclear opacities. (3) BCVA >= 0.8, IOP <= 21 mmHg, no history of glaucoma or evidence of optic nerve damage. (4) Data completeness: Has complete and high-quality OCT and OCTA examination records. (5) General condition: No known systemic diseases that affect retinal microcirculation (such as diabetes, uncontrolled hypertension).
Exclusion criteria
Exclusion criteria: 1. wAMD group: (1) CNV not caused by wAMD. (2) Pathological myopia-induced mCNV, polypoidal choroidal vasculopathy (PCV), inflammatory (such as uveitis) or infectious CNV, idiopathic CNV. (3) Comorbid with other fundus diseases: coexisting with diabetic retinopathy (DR), retinal vein occlusion (RVO), etc., other vascular diseases that may affect the morphology or blood flow of the macula. Comorbid with cystoid macular edema (CSC), macular hole, significant epiretinal membrane (ERM), or vitreomacular traction (VMT). (4) Baseline already had a clear subfoveal map-like atrophy (GA). (5) Refractive media: presence of refractive media opacity that severely affects image quality (such as severe cataract, corneal opacity, vitreous hemorrhage). (6) Comorbid with glaucoma: diagnosed glaucoma or visual field defect, or baseline IOP > 21mmHg. (7) Surgical history: the study eye had an intraocular surgery history within 6 months before the baseline (such as cataract surgery, vitrectomy, etc.). (8) Data missing: OCT/OCTA data at the baseline or key follow-up time points (such as after loading treatment) are missing or of poor quality. 2. Control group: (1) Any AMD manifestation: presence of any AMD signs (such as medium-large choroidal nevus, fused choroidal nevus, pigment epithelial abnormalities, etc.) except for a few small hard warts. (2) Refractive error: high myopia. Comorbid with other eye diseases: any eye disease that may affect the structure or blood flow of the macula (such as DR, RVO, ERM, uveitis, etc.). (3) Refractive media: presence of obvious refractive media opacity that significantly affects image quality. (4) Surgical history: previous intraocular surgery history. (5) Image quality: OCT/OCTA image quality is not up to standard or has obvious artifacts.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Optical coherence tomography angiography;Optical coherence tomography; | — |
Countries
China
Contacts
Public ContactLv Lin
The Zhongshan Ophthalmic Center,Sun Yat-sen University
Outcome results
None listed